Displaying drugs 1326 - 1350 of 2538 in total
AZD-9056
AZD9056 has been used in trials studying the basic science and treatment of Rheumatoid Arthritis.
Investigational
AZD-9496
AZD-9496 is under investigation in clinical trial NCT02248090 (AZD9496 First Time in Patients Ascending Dose Study).
Investigational
CP-96345
Experimental
ZK-93423
ZK-93423 is a beta-carboline with muscle relaxant activity with agonistic properties at the benzodiazepine receptor.
Investigational
BLU-9931
Investigational
CC-90001
Investigational
Skf 107457
Experimental
ILY101
ILY101 is a metal-free, non-absorbed polymeric drug designed for the selective binding and removal of phosphate anions from the gastrointestinal tract. ILY101 is being developed for the treatment of hyperphosphatemia in CKD patients on dialysis and works by reducing the systemic absorption of dietary phosphate. ILY101 is designed to allow...
Investigational
AEOL-10150
AEOL 10150 is developed by Aeolus as a therapeutic agents based on its proprietary small molecule catalytic antioxidants.
Investigational
PA-1050040
PA1050040, a second generation HIV-1 maturation inhibitor, is a chemical analog of Bevirimat (BVM). It inhibits virus replication by the same mechanism of action as BVM.
Investigational
CXD101
CXD101 is under investigation in clinical trial NCT03873025 (A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-cell Lymphoma).
Investigational
DSP107
DSP107 is a bi-functional, trimeric, fusion protein composed of sequences from the extracellular domain of SIRPĪ± and 4-1BBL.
Investigational
SIS-101-ADO
SIS-101-ADO is a siRNA therapeutic under investigation for the treatment of Autosomal Dominant Osteopetrosis Type 2 (ADO2).
Investigational
NKX101
NKX101 is an investigational allogeneic chimeric antigen receptor (CAR)-natural killer cell therapy.
Investigational
AXV101
Investigational
Parsatuzumab
Parsatuzumab is under investigation in clinical trial NCT01366131 (Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE)).
Investigational
Yttrium Y-90 epratuzumab tetraxetan
Investigational
MB-07803
MB07803 is a second generation gluconeogenesis inhibitor for the treatment of type 2 diabetes. It is designed to block the metabolic pathway in the liver that is responsible for producing glucose.
Investigational
MBT-0312
MediGene's newly acquired drug candidates MBT-0312 aim at a novel method of cancer therapy by "starving out" tumors.
Investigational
AZD-0424
AZD0424 has been used in trials studying the treatment of Advanced Solid Tumours.
Investigational
GDC-0927
GDC-0927 is under investigation in clinical trial NCT02316509 (A Study of GDC-0927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer).
Investigational
VM4-037
VM4-037 is under investigation in clinical trial NCT00884520 (An Exploratory, Open Label, Multi-Center, Non-Randomized Study of [F-18]VM4-037).
Investigational
SOBI-003
SOBI-003 is a chemically modified variant of a recombinant human sulfamidase. It is under investigation in clinical trial NCT03811028 (A Study to Assess the Safety, Tolerability, and Efficacy of Long-term SOBI003 Treatment in Pediatric MPS IIIA Patients).
Investigational
YS-ON-001
YS-ON-001 is a combination of an inactivated purified rabies virus (IPRV) and the PIKA adjuvant (Poly I:C, kanamycin and calcium).
Investigational
Displaying drugs 1326 - 1350 of 2538 in total